

**MANALTO LIMITED ACN 098 640 352  
(FORMERLY HEALTHLINX LIMITED)**

23 March 2015

**PRE-LISTING DISCLOSURES**

The following information is provided by Manalto Limited (**the Company**) for release to the market:

**DISTRIBUTION SCHEDULE AND TOP 20 HOLDERS**

A distribution schedule of the holders of ordinary shares forms part of this release together with a statement setting out the names of the 20 largest holders of the Company's ordinary shares (including the number and percentage of each class of securities held by those holders).

**SECURITIES SUBJECT TO ESCROW**

Security	Escrow Period	Number
Ordinary shares	24 months from the date of reinstatement of official quotation of the shares.	14,401,395
Ordinary shares	Until 18 May 2015.	319,862
Ordinary shares	Until 19 May 2015.	158,029
Ordinary shares	Until 20 May 2015.	234,595
Ordinary shares	Until 2 June 2015.	312,547
Ordinary shares	Until 12 June 2015.	159,632
Ordinary shares	Until 5 January 2016.	134,785
Options (exercisable at \$0.25 expiring 11 March 2018)	24 months from the date of reinstatement of official quotation.	2,250,000
Options (exercisable at \$0.25 expiring 11 March 2020)	24 months from the date of reinstatement of official quotation.	4,550,000

**NO MATERIAL ADVERSE EVENT**

The Company confirms there has been no material subsequent events to alter the Company's statement of financial position as detailed on page 31 of the Replacement Prospectus dated 29 January 2015 (**Prospectus**).

## REVIEWED ACCOUNTS FOR MANALTO INC.

The reviewed accounts for Manalto Inc. for the period ended 30 September 2014 form part of this release.

## COMPLETION OF ACQUISITION AND ISSUE OF SHARES AND OPTIONS

As noted in the Company's market update announcement on 12 March 2015, the Company has completed its acquisition of Manalto Inc. and all conditions to that acquisition have been satisfied. Accordingly, as noted in the Appendix 3B lodged 12 March 2015, the Company has issued:

- 62,499,998 fully paid ordinary shares to the shareholders of Manalto Inc.;
- 2,250,000 options to advisors; and
- 8,000,000 options to key management and employees;

pursuant to the approvals obtained by shareholders at the Company's general meeting held on 23 February 2015 and as described in the Prospectus.

## SUMMARY OF CAPITAL STRUCTURE

### Shares (post-consolidation)

HTX ordinary shares (pre-transaction).	5,554,592
Consideration shares issued to Manalto Inc. shareholders.	62,499,998
Shares issued to investors in capital raising.	30,000,000
<b>TOTAL (including restricted ordinary shares)</b>	<b>98,054,590</b>

### Options (post-consolidation)

Exercisable at \$0.25 cents expiring 11 March 2018.	2,250,000
Exercisable at \$0.25 cents expiring 11 March 2020.	8,000,000
Various exercise prices between \$1.50 and \$12.50, expiry dates between 19 March 2015 and 30 April 2016.	10,410
<b>TOTAL</b>	<b>10,260,410</b>

Full terms of the options issued under the Prospectus and a copy of the Company's Employee Share Option Plan form part of this release.

## UPDATED STATEMENT OF FINANCIAL POSITION

A statement of financial position based on the actual amount of funds raised (being \$6 million before costs) extracted from the Prospectus forms part of this release.

## UPDATED STATEMENT OF COMMITMENTS

The use of funds table set out in the Prospectus is updated for actual funds received as follows:

Use of Funds	Year 1	Year 2	Total
Costs of Offer	\$734,500	Nil	\$734,500

	(12.24%)			(12.24%)
Research and Development Staff				
Customer support:	300,000		312,000	612,000
Software development:	378,000		378,000	756,000
Other:*	42,000		30,000	72,000
Total Research and Development	\$720,000 (12%)		\$720,000 (12%)	\$1,440,000 (24%)
Sales and Marketing Staff^	1,267,750 (21.13%)		1,267,750 (21.13%)	2,535,500 (42.26%)
General and Administration	\$804,000 (13.4%)		\$486,000 (8.1%)	\$1,290,000 (21.5%)
<b>TOTAL</b>	<b>\$3,526,250 (58.77%)</b>		<b>\$2,473,750 (41.23%)</b>	<b>\$6,000,000 (100%)</b>

\* Includes Research and Development Staff support costs of (e.g. third party providers for testing and incidental costs).

^ Includes fees of CEO and \$300,000 in Year 1 and \$280,000 in Year 2 for Sales and Marketing Staff support costs (eg attendance at and participation in conferences, marketing and advertising media costs, and website development).

## COMPLIANCE WITH LISTING RULES

The Company confirms that it is in compliance with the ASX Listing Rules and in particular ASX Listing Rule 3.1.